A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Completed · Phase 3

Conditions studied: Mixed Dyslipidemia

In brief

The objective of the study is to assess the continued safety of the daily coadministration of ABT-335 in combination with rosuvastatin calcium, simvastatin or atorvastatin calcium.

Key facts

Study ID

NCT00491530

Run by

Abbott

People needed

310

Starts

2007-06-01

Expected to finish

2008-11-01

Last updated by the study team

2012-01-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult male and female subjects who voluntarily sign the informed consent.
• Subject has successfully completed the treatment phase of the preceding open-label year 1 study.

You may not qualify if…

• Subject is using or will use investigational medications, except as approved by Abbott.
• Subject has prematurely discontinued his/her combination therapy administered in the preceding open-label year 1 study.

Where it is running

• Medical Information Specialist — Abbott Park, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.